WARREN, N.J., May 14 /PRNewswire/ -- MonoSol Rx, Inc., announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company. The number of shares of common stock and price per share to be sold have not yet been determined.
Cowen and Company is the sole book-running manager for the offering. CIBC World Markets and Susquehanna Financial Group, LLLP are co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This offering will be made only by means of a prospectus. When available, a copy of the prospectus for the above offering can be obtained by eligible investors from their Cowen and Company sales representative, or from the offices of Cowen and Company, LLC c/o ADP., 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Dept. (631) 254-7106.
About MonoSol Rx, Inc.
MonoSol Rx, Inc. is a drug delivery company specializing in proprietary thin film pharmaceutical products for prescription and over-the-counter drugs.
Source: MonoSol Rx, Inc.
